Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01)
Success for Apmonia Therapeutics’ technology platform developing a portfolio of therapeutic peptides targeting tumor microenvironment in solid tumors
![](http://apmonia-therapeutics.com/wp-content/uploads/2022/02/ApmoniaTx_PressRelease_20220210_Page_1-728x1024.jpg)
![](http://apmonia-therapeutics.com/wp-content/uploads/2022/02/ApmoniaTx_PressRelease_20220210_Page_2-728x1024.jpg)
![](http://apmonia-therapeutics.com/wp-content/uploads/2022/02/ApmoniaTx_PressRelease_20220210_Page_3-728x1024.jpg)